Abstract: The present invention relates to a method of manufacturing an alveolar organoid using alveolar cell-derived induced pluripotent stem cells. The alveolar organoid manufactured according to the present invention is differentiated from the human alveolar cell-derived induced pluripotent stem cells, and thus induced pluripotent stem cells may efficiently differentiate into alveolar organoids due to the epigenetic memory of alveolar cells. Therefore, the alveolar organoids are expected to be effectively used for research on the pathological process of respiratory diseases, screening for finding therapeutic drugs, and the like.

Abstract: The present disclosure discloses an electrokinetic-based apparatus for filtering charged particles. The apparatus includes a main channel through which a fluid containing charged particles is injected and flows, a first electrode disposed to allow the flow of fluid inside the main channel, and an ion exchange membrane disposed downstream of the first electrode and having a plurality of pores through which the fluid from which the charged particles have been filtered is discharged.

Abstract: The present invention relates to a method of developing a tissue-specific vascular endothelial cell line based on iPSCs derived from human tissue-specific cells. When an organoid is manufactured using the cell line based on the iPSCs derived from human tissue-specific cells, the organoid manufacturing period may be significantly shortened, thereby solving the problem of sustainability, which is a major drawback known in the related art, and may be stored conveniently, and thus may be easily used during each experiment, thereby greatly increasing efficiency. Also, the organoid manufactured from the cell line of the present invention may be usefully used in the manufacture of blood vessel organoids in that the organoid is not only tissue-specific but also exhibits an excellent level of morphological and functional maturity.

Abstract: Disclosed is a method of producing vascularized respiratory (airway and alveolar) organoids using blood vessel organoids. More particularly, vascularized respiratory (airway and alveolar) organoids with a vascular network are produced by fusing respiratory (airway and alveolar) organoids with blood vessel organoids to induce vascularization. The vascularized respiratory (airway and alveolar) organoids can have functions very similar to the human respiratory whole region, so they are expected to be transplanted into humans to treat respiratory related diseases or be used as an in vitro respiratory whole region model.

Abstract: The present invention relates to a method of producing an alveolar organoid by a dropping suspension culture technique using decellularized extracellular matrix (dECM) hydrogel, and according to the present invention, when an organoid is produced by a dropping suspension culture method using dECM, as in a living organism, an organoid in which cells and dECM are fused may be formed. Moreover, since dECM is what remains after all cells have been removed from tissue and thus is easily applied clinically, the produced organoid is expected to be useful for disease modeling, drug screening, regenerative medicine, etc.

Abstract: The present invention relates to a lung cancer model based on a normal lung organoid, prepared by fusing cancer cells to the normal lung organoid. By using the lung cancer model according to the present invention, it is possible not only to observe the progression or metastasis pattern of lung cancer from the early stage of proliferating lung cancer cells to the stage of forming a tumor but also to compare the effect of an anticancer agent at each stage, and thus the information on an appropriate therapeutic agent may be provided according to the stage of cancer development. In addition, since the lung cancer model according to the present invention includes a normal lung organoid and cancer cells, which are fused, it can be effectively used to confirm the effect of an anticancer agent on normal tissue and the effect of cancer cell-specific apoptosis.